Individualised and Equitable Care of Type 2 Diabetes

Informations projet

EASY-Diabetes

N° de convention de subvention: 877170

DOI

10.3030/877170

Projet clôturé

Date de signature de la CE 23 Octobre 2019

Date de début 1 Novembre 2019

Date de fin 29 Février 2020

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

ADJUVIA AB
Sweden

Periodic Reporting for period 1 - EASY-Diabetes (Individualised and Equitable Care of Type 2 Diabetes)

Période du rapport: 2019-11-01 au 2020-02-29

Résumé du contexte et des objectifs généraux du projet

Diabetes is a common chronic disease that causes suffering for patients and vast costs for society. We have developed an e-health solution for diabetes that aims to improve patient outcomes, save time for healthcare professionals and reduce costs for society. Our SME Phase 1 feasibility study aimed to validate the commercial feasibility of our product with target market segments and key stakeholders. It included financial planning and specification of product features.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

In the project, we have assessed the technical, commercial and financial feasibility of introducing our product to the market. This included identifying features needed for a fully commercialised solution, target markets and stakeholders. We have developed a strategy for introducing our product to the market, including regulatory requirements, operating costs and revenue projections.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The outcomes of the project resulted in improvements to our plan for the next phase of the business. These improvements include changing some of our target markets, enhancing our implementation models and changing our cooperative strategy. We are thus in a better position to realise the long-term impact of our offering in terms of patient health, healthcare savings and job creation.

Logo for the product